Caprock Group LLC Reduces Holdings in Accuray Incorporated (NASDAQ:ARAY)

Caprock Group LLC cut its stake in shares of Accuray Incorporated (NASDAQ:ARAY) by 25.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 15,000 shares of the medical equipment provider’s stock after selling 5,000 shares during the period. Caprock Group LLC’s holdings in Accuray were worth $30,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ARAY. AQR Capital Management LLC purchased a new stake in Accuray during the 2nd quarter worth about $30,000. US Bancorp DE increased its stake in shares of Accuray by 1,087.7% during the third quarter. US Bancorp DE now owns 17,816 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 16,316 shares during the period. Intech Investment Management LLC acquired a new stake in Accuray in the third quarter valued at approximately $41,000. Thrivent Financial for Lutherans purchased a new position in Accuray in the third quarter worth approximately $57,000. Finally, SG Americas Securities LLC acquired a new position in Accuray during the 3rd quarter worth approximately $59,000. 64.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Trading Down 9.7 %

ARAY opened at $2.43 on Friday. The company has a debt-to-equity ratio of 3.59, a quick ratio of 0.87 and a current ratio of 1.63. Accuray Incorporated has a one year low of $1.40 and a one year high of $2.95. The company has a market cap of $244.39 million, a P/E ratio of -14.29 and a beta of 1.51. The business’s 50-day simple moving average is $2.11 and its 200-day simple moving average is $1.97.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. As a group, equities research analysts expect that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.